

## Letter to the Editor

## Comment on “Risk factors associated with the use of red blood cells in elective cardiac surgeries”

1	Dear Editor,	
Q12	We herein discuss the publication on “Risk factors associated with the use of red blood cells in elective cardiac surgeries: A patient blood management (PBM) view”. [1] This article investigates the risk variables linked with the use of packed red blood cells (PRBC) in patients undergoing elective heart surgery in Brazil.	
8	While stepwise logistic regression results show that female gender, poor hematocrit level, diabetes, and extracorporeal circulation duration of more than 90 min are significant risk variables, this analysis is statistically limited. As this is a retrospective study, it is susceptible to bias from data collection or sample selection. Furthermore, stepwise logistic regression may result in overfitting and variable selection based on the specific data set, restricting its applicability to other hospitals or populations.	
16	Furthermore, underlying heart disease severity, changes in surgeon treatment, surgical technique, or anticoagulant use can all have an impact on the accuracy of the outcomes as these variables may not be recorded or controlled in the analysis. Furthermore, the identification of female gender as a high-risk factor could be explained by variations in body weight or total blood volume, however the paper did not account for these variables in its analysis. This may confound the relationship.	
24	New interpretations may concentrate on synthesizing findings for PBM guidelines. Preoperative hematocrit assessment and improvement of anemia, diabetes management, and surgical planning to limit cardiopulmonary bypass time can all help to lessen the requirement for PRBC. Furthermore, including risk prediction models that take into account characteristics such as gender, body weight, disease severity, and laboratory results might improve accuracy and simplify effective blood use planning.	
33	To broaden the topic, consider the following research questions:	
35	1) Can this retrospective study be transformed into a prospective or multicenter study to corroborate the relationship?	
36		38
37		39
		40
		41
		42
		43
		44
		45
		46
		47
	These questions may lead to applicable research as well as safe, resource-saving strategies in Brazil's health-care system.	
		45
		46
		47
	<b>Data availability statement</b>	48
	there is no new data generated	49
	<b>Funding statement</b>	50
	there is no funding	51
	<b>Ethics of approval statement</b>	52
	not applicable	53
	<b>Patient consent statement</b>	54
	not applicable	55
	<b>Permission to reproduce material from other sources</b>	56
	not applicable	57
		58

59 **Clinical trial registration**

60 not applicable

61 **Author contributions**62 HP 50 % ideas, writing, analyzing, approval  
63 VW 50 % ideas, supervision, approval64 **AI declaration**65 the authors use computation tool in language checking and  
66 editing.67 **Conflicts of interest**

68 the authors declare no conflict of interest

69 **REFERENCES**70 [1]. Souza TM, Miranda CL, Castro AB, Garcia-Bonichini PC. Risk  
71 factors associated with the use of red blood cells in electivecardiac surgeries: a patient blood management (PBM) view. 72  
Hematol Transfus Cell Ther. 2025 Sep 17;47(4):103987. <https://doi.org/10.1016/j.htct.2025.103987>. Online ahead of print. 73  
74Hinpetch Daungsupawong  <sup>a,\*</sup>, Viroj Wiwanitkit  <sup>b</sup><sup>a</sup> Phonhong, Lao People's Democratic Republic 76<sup>b</sup> Department of Research Analytics, Saveetha Dental College and 77  
Hospitals, Saveetha Institute of Medical and Technical Sciences 78  
Saveetha University, Chennai, India 79

\*Corresponding author at: Private Academic Consultant, 80

Phonhong, Vientiane 10000 Lao People's Democratic Republic. 81

E-mail address: [hinpetchdaung@gmail.com](mailto:hinpetchdaung@gmail.com) 82

(H. Daungsupawong). 83

Received 20 September 2025 84

Accepted 21 October 2025 85

Available online xxxx 86

<https://doi.org/10.1016/j.htct.2025.106236> 87

2531-1379/ 88

© 2025 Associação Brasileira de Hematologia, Hemoterapia e 89  
Terapia Celular. Published by Elsevier España, S.L.U. This is an 90  
open access article under the CC BY license 91  
(<http://creativecommons.org/licenses/by/4.0/>). 92